Based on these large clinical trials, SGLT2 inhibitors are recommended for high-risk DKD patients with an estimated GFR of >30 mL/min/1.73 m2 or urinary albumin excretion >30 mg/g creatinine (particularly >300 mg/g creatinine), to reduce the risk of DKD progression [3,62]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.